
## Yong Fang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2676260/publications.pdf

Version: 2024-02-01



YONG FANG

#	Article	IF	CITATIONS
1	Whole-Process Treatment of Combined Small Cell Lung Cancer Initially Diagnosed as "Lung Squamous Cell Carcinomaâ€i A Case Report and Review of the Literature. Frontiers in Immunology, 2022, 13, 831698.	4.8	3
2	Comprehensive Molecular Profiling of Colorectal Cancer With Situs Inversus Totalis by Next-Generation Sequencing. Frontiers in Oncology, 2022, 12, 813253.	2.8	1
3	The efficacy and safety of taletrectinib in patients with TKI-naÃ⁻ve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2022, 40, 8572-8572.	1.6	4
4	A Light-weight High-accuracy 4-DOF Robot for CT-image Guided Percutaneous Interventions. , 2022, , .		2
5	Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial. Journal of Thoracic Oncology, 2021, 16, 299-309.	1.1	72
6	CT-guided percutaneous minimally invasive radiofrequency ablation for the relief of cancer related pain from metastatic non-small cell lung cancer patients: a retrospective study. Annals of Palliative Medicine, 2021, 10, 1494-1502.	1.2	5
7	Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib. Frontiers in Oncology, 2021, 11, 628693.	2.8	3
8	Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST Journal of Clinical Oncology, 2021, 39, 9066-9066.	1.6	7
9	Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC). Cancer Research, 2021, 81, CT041-CT041.	0.9	3
10	Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non–Small-Cell Lung Cancer Patients Treated With the Anti–PD-L1 Antibody. Frontiers in Molecular Biosciences, 2021, 8, 679130.	3.5	11
11	Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). Journal of Thoracic Oncology, 2021, 16, 1533-1546.	1.1	64
12	Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma. Cancer Science, 2021, 112, 4758-4771.	3.9	7
13	Exploring the Interobserver Agreement in Computer-Aided Radiologic Tumor Measurement and Evaluation of Tumor Response. Frontiers in Oncology, 2021, 11, 691638.	2.8	0
14	Expert consensus on thermal ablation therapy of pulmonary subsolid nodules (2021 Edition). Journal of Cancer Research and Therapeutics, 2021, 17, 1141.	0.9	23
15	Realâ€world efficacy and potential mechanism of resistance of icotinib in Asian advanced nonâ€small cell lung cancer with EGFR uncommon mutations: A multiâ€center study. Cancer Medicine, 2020, 9, 12-18.	2.8	10
16	A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations. Translational Oncology, 2020, 13, 329-335.	3.7	24
17	Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Translational Lung Cancer Research, 2020, 9, 1853-1861.	2.8	18
18	A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 4511-4520.	7.0	56

Yong Fang

#	Article	IF	CITATIONS
19	An ultralow dose of the NADPH oxidase inhibitor diphenyleneiodonium (DPI) is an economical and effective therapeutic agent for the treatment of colitis-associated colorectal cancer. Theranostics, 2020, 10, 6743-6757.	10.0	20
20	Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi enter study. Cancer Science, 2020, 111, 679-686.	3.9	15
21	A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101 Journal of Clinical Oncology, 2020, 38, e21705-e21705.	1.6	7
22	Real-world mutational profiling of Chinese non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) uncommon mutations acquired resistant to icotinib using next generation sequencing: A multicenter study Journal of Clinical Oncology, 2020, 38, e21557-e21557.	1.6	0
23	<i>TP53</i> fusions with next-generation sequencing (NGS) in Chinese non-small cell lung cancer (NSCLC): A multicenter study Journal of Clinical Oncology, 2020, 38, e21742-e21742.	1.6	0
24	APC fusions analysis in Chinese non-small cell lung cancer (NSCLC) using comprehensive NCS panel: A multicenter study Journal of Clinical Oncology, 2020, 38, e21086-e21086.	1.6	0
25	CSCO ablation expert workshop report. Journal of Cancer Research and Therapeutics, 2020, 16, 350-355.	0.9	1
26	Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non- small cell lung cancer patients: a multicenter retrospective study. Translational Cancer Research, 2020, 9, 6039-6049.	1.0	1
27	Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase ( <i><scp>ALK</scp></i> )â€rearranged nonâ€small cell lung cancer. Cancer Science, 2019, 110, 3382-3390.	3.9	26
28	Ultrasonic Cavitation Ameliorates Antitumor Efficacy of Residual Cancer After Incomplete Radiofrequency Ablation in Rabbit VX2 Liver Tumor Model. Translational Oncology, 2019, 12, 1113-1121.	3.7	6
29	Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway. EBioMedicine, 2019, 42, 326-339.	6.1	14
30	Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials. Journal of Cancer, 2019, 10, 968-978.	2.5	9
31	Deletion of low-density lipoprotein-related receptor 5 inhibits liver Cancer cell proliferation via destabilizing Nucleoporin 37. Cell Communication and Signaling, 2019, 17, 174.	6.5	14
32	Incidence of FGFR-TACC gene fusions in Chinese non-small cell lung cancer (NSCLC): A multicenter study Journal of Clinical Oncology, 2019, 37, e13001-e13001.	1.6	1
33	Real-world large-scale study of ERBB2 gene fusions and its response to afatinib in Chinese non-small cell lung cancer (NSCLC): A multicenter study Journal of Clinical Oncology, 2019, 37, e13002-e13002.	1.6	2
34	Real-world fusion landscape in advanced Chinese gastric cancer using next generation sequencing: A multicenter study Journal of Clinical Oncology, 2019, 37, 51-51.	1.6	0
35	Mechanisms of primary resistance to icotinib in Chinese non-small-cell lung cancer patients with EGFR uncommon mutations: A multicenter study Journal of Clinical Oncology, 2019, 37, e20501-e20501.	1.6	0
36	An EGFR extracellular domain mutation data in the East Asian non-small cell lung cancer populations and response to icotinib: A multicenter study Journal of Clinical Oncology, 2019, 37, e13000-e13000.	1.6	0

Yong Fang

#	Article	IF	CITATIONS
37	ldentification of key tumorigenesis‑related genes and their microRNAs in colon cancer. Oncology Reports, 2018, 40, 3551-3560.	2.6	23
38	Multiple Primary Malignant Tumors - A Clinical Analysis of 15,321 Patients with Malignancies at a Single Center in China. Journal of Cancer, 2018, 9, 2795-2801.	2.5	58
39	Genetic mutation as biomarker for advanced cancer patients receiving apatinib: An analysis based on whole exome sequencing Journal of Clinical Oncology, 2018, 36, e24219-e24219.	1.6	О
40	Deep sequencing of the t-cell receptors for monitoring peripheral CD8 <sup>+T</sup> cells in advanced NSCLC Chinese patients treated with anti-PD-L1 antibody Journal of Clinical Oncology, 2018, 36, e15025-e15025.	1.6	0
41	Beta-catenin can induce hair follicle stem cell differentiation into transit-amplifying cells through c-myc activation. Tissue and Cell, 2017, 49, 28-34.	2.2	23
42	Quantitation of cell-free DNA in blood is a potential screening and diagnostic maker of breast cancer: a meta-analysis. Oncotarget, 2017, 8, 102336-102345.	1.8	3
43	Salvianolic acid B, a novel autophagy inducer, exerts antitumor activity as a single agent in colorectal cancer cells. Oncotarget, 2016, 7, 61509-61519.	1.8	59
44	p53 suppresses stress-induced cellular senescence via regulation of autophagy under the deprivation of serum. Molecular Medicine Reports, 2015, 11, 1214-1220.	2.4	13
45	Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. Scientific Reports, 2015, 5, 8897.	3.3	59
46	p53 controls colorectal cancer cell invasion by inhibiting the NF-κB-mediated activation of Fascin. Oncotarget, 2015, 6, 22869-22879.	1.8	20
47	Epigenetic modifications as regulatory elements of autophagy in cancer. Cancer Letters, 2015, 360, 106-113.	7.2	58
48	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget, 2015, 6, 19393-19404.	1.8	61
49	Autophagy: A novel therapeutic target for hepatocarcinoma (Review). Oncology Letters, 2014, 7, 1345-1351.	1.8	28
50	Construction of a tumor cell-targeting non-viral gene delivery vector with polyethylenimine modified with RGD sequence-containing peptide. Oncology Letters, 2014, 7, 487-492.	1.8	19
51	Comparison of longâ€ŧerm effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 193-200.	2.8	138
52	Enzyme activated photodynamic therapy for methicillin-resistant Staphylococcus aureus infection both inv itro and in vivo. Journal of Photochemistry and Photobiology B: Biology, 2014, 136, 72-80.	3.8	25
53	Use of Metformin Alone Is Not Associated with Survival Outcomes of Colorectal Cancer Cell but AMPK Activator AICAR Sensitizes Anticancer Effect of 5-Fluorouracil through AMPK Activation. PLoS ONE, 2014, 9, e97781.	2.5	44
54	Cyclin D1 Downregulation Contributes to Anticancer Effect of Isorhapontigenin on Human Bladder Cancer Cells. Molecular Cancer Therapeutics, 2013, 12, 1492-1503.	4.1	49

#	Article	IF	CITATIONS
55	The Chinese Herb Isolate Isorhapontigenin Induces Apoptosis in Human Cancer Cells by Down-regulating Overexpression of Antiapoptotic Protein XIAP. Journal of Biological Chemistry, 2012, 287, 35234-35243.	3.4	57